Nexavar Significantly Improves Overall Survival By 47 Percent In Asia Pacific Liver Cancer Study

                   
medicalnewstoday.com     May 17, 2008            

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that Nexavar(R) (sorafenib) tablets significantly improved overall survival by 47.3 percent (HR=0.68; p-value=0.014) in patients in the Asia-Pacific region with advanced hepatocellular carcinoma (HCC),... [read full story]                    

Full Coverage
                   

Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology...

prnewswire.com     May 16, 2008          

Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting WAYNE, N.J. and EMERYVILLE, Calif., May 16 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced more than 40...                    

comments

                   

Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study

prnewswire.com     May 16, 2008          

Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study - Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that Nexavar(R) (sorafenib) tablets significantly improved overall survival by 47.3 percent...                    

comments

                   

16.05.08: Bayer and Onyx Announce Nexavar® Data Presentations at 44th American Society of...

bayer.com     May 16, 2008          

Berlin, May 16, 2008 - Randomized Phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma o Ann Lii-Cheng, MD, PhD, department of internal medicine, National Taiwan University Hospital, Taipei, Taiwan o Abstract #4509, oral presentation, Monday, June...                    

comments

                   

16.05.08: Phase III Asia-Pacific Study:

bayer.com     May 16, 2008          

Nexavar Significantly Extends Overall Survival in Liver Cancer by 47 percent Trial Results Confirm Efficacy for Population Most Affected by the Disease Berlin, May 16, 2008 - Bayer HealthCare and Onyx Pharmaceuticals, Inc. today announced that Nexavar® (sorafenib) tablets significantly improved...                    

comments